NCT05752461View on ClinicalTrials.gov

SHR-2004 for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

PHASE2CompletedINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

April 12, 2024

Study Completion Date

June 25, 2024

Conditions
Prevention of Venous Thromboembolism After Knee Arthroplasty
Interventions
DRUG

SHR-2004 injection

low dose subcutaneous injection once

DRUG

SHR-2004 injection

medium dose subcutaneous injection once

DRUG

SHR-2004 injection

high dose subcutaneous injection once

DRUG

Enoxaparin sodium injection

40 mg administered as subcutaneous injection once daily

Trial Locations (1)

410008

Xiangya Hospital Central South University, Changsha

All Listed Sponsors
lead

Beijing Suncadia Pharmaceuticals Co., Ltd

INDUSTRY